Trial · NCT04790786
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hospital-free Days | 28 days after initial participation | Days alive and free from hospitalization. Patients that are both living and not in the hospital will meet criteria to be counted in this outcome. Deaths were rare and therefore the upper and lower end of the IQR are both 28, in addition to the median. This outcome measure does reflect median hospital free days and interquartile ranges for all groups. |
| Secondary | All-cause Mortality at 28 Days | 28 days after initial participation | All-cause mortality at 28 days. |
| Secondary | SARS-CoV-2 Nasopharyngeal Viral Loads | 28 days after initial participation | Where feasible SARS-CoV-2 nasopharyngeal viral loads among participants from baseline and longitudinally through day 28 |
| Secondary | SARS-CoV-2 Plasma Viral Loads | 28 days after initial participation | Where feasible SARS-CoV-2 plasma viral loads among participants from baseline and longitudinally through day 28 |
| Secondary | SARS-CoV-2 Antibody Titers | 28 days after initial participation | Where feasible SARS-CoV-2 antibody titers at baseline and longitudinally through day 28 |
| Secondary | SARS-CoV-2 Antibody Neutralization | 28 days after initial participation | Where feasible SARS-CoV-2 antibody neutralization at baseline and longitudinally through day 28 |
| Secondary | SARS-CoV-2 Immune Responses | 28 days after initial participation | Where feasible SARS-CoV-2 immune responses at baseline and longitudinally through day 28 |
| Secondary | Detection of SARS-CoV-2 Variants Through Next-generation Sequencing | 28 days after initial participation | Where feasible detection of SARS-CoV-2 variants through next-generation sequencing at baseline and longitudinally through day 28 |
| Secondary | Duration of SAR-CoV-2 Infectivity | 28 days after initial participation | Where feasible determining the duration of SAR-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding |
| Secondary | Non-culture Surrogates for SARS-CoV-2 Infectivity | 28 days after initial participation | Where feasible determining non-culture surrogates for SARS-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding |
| Secondary | Non-culture Surrogates for SARS-CoV-2 Infectivity | 90 days after initial participation | Where feasible determining non-culture surrogates for SARS-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding |
| Secondary | Duration of SAR-CoV-2 Infectivity | 90 days after initial participation | Where feasible determining the duration of SAR-CoV-2 infectivity among patients with persistent nasopharyngeal swab viral shedding |
| Secondary | ED Visit Within 28 Days | Duration of study |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04790786/registered